CTRI/2025/09/095120尚未招募4 期
Comparing Sugammadex with Neostigmine for reversal of rocuronium-induced neuromuscular blockade: a randomized controlled study
Indraprastha Apollo Hospital, New Delhi1 个研究点 分布在 1 个国家目标入组 42 人开始时间: 2025年9月23日最近更新:
试验速览
- 阶段
- 4 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 42
- 试验地点
- 1
- 主要终点
- Time required to reach train of four ratio to 0.9 after the administration of sugammadex or neostigmine
研究概览
简要总结
In this study, we will compare the safety and efficacy of sugammadex over neostigmine for the reversal of rocuronium-induced neuromuscular block. We also intend to assess the risk of postoperative residual paralysis and adverse effects of neostigmine and sugammadex.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 盲法
- None
入排标准
- 年龄范围
- 18.00 Year(s) 至 99.00 Year(s)（—）
- 性别
- All
入选标准
- •ASA (American Society of Anaesthesiologists), physical status 1 and 3 Age more than 18 years Any surgical procedure under general anesthesia with rocuronium and requiring reversal.
排除标准
- •Hypersensitivity to any drugs/cyclodextrins Difficult intubation Neuromuscular disorder/neurodegenerative disorders Severe renal and hepatic dysfunction History of Malignant hyperthermia Pregnancy Chronic obstructive airway disease.
结局指标
主要结局
Time required to reach train of four ratio to 0.9 after the administration of sugammadex or neostigmine
时间窗: Every 15 minutes till TOF more than equal to 0.9 and at 2 hours after extubation
次要结局
- Postoperative residual paralysis,(Adverse effects of neostigmine and sugammadex)
研究者
Dharitri Dutta
Indraprastha Apollo Hospital, New Delhi
研究点 (1)
Loading locations...
相似试验
尚未招募
4 期
Assessment of reversal time characteristics using full dose with two step administration of Neostigmine for antagonizing Atracurium induced moderate block using neuromuscular monitor –Double blinded randomized control trialCTRI/2025/08/093752Pondicherry Institute of Medical Sciences .88
招募中
3 期
A study to compare pharmacokinetics, efficacy, safety, and immunogenicity of MB12 (proposed pembrolizumab biosimilar) to Keytruda® in non-small cell lung cancer2024-515853-48-00Mabxience Research S.L.269
已完成
2 期
Effects of NNC0194-0499, cagrilintide, and semaglutide alone or in combinations on liver damage and alcohol use in people with alcohol-related liver disease2023-508170-28-00Novo Nordisk A/S140
已完成
不适用
Impact Of Using LevosemidanVersus DobutamineOn Right Ventricular Function In AdultPatients Undergoing Elective Valve Replacement SurgeryPulmonary HypertensionNCT07416331Helwan University52
招募中
4 期
Comparison of Mirabegron and Tamsulosin for Ureteral Stone ExpulsionUreteral CalculiNCT07310797Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation500